Inside Alcidion Group’s (ASX: ALC) Massive $35M UK Win and Bargain M&A Deal

Key Highlights

• Alcidion secures NHS contract worth up to $49 million over 10 years
• $8.5 million expected to be recognised in FY26 revenue
• Company acquires Telstra Health assets at low 2.7x EBITDA multiple
• Deal adds 33 enterprise healthcare customers across Australia
• Shares edge higher as market digests dual growth announcements

Healthcare software group Alcidion Group is emerging from a busy fortnight with two announcements that significantly expand both its scale and recurring revenue profile.

The company on Monday confirmed a major UK healthcare contract potentially worth up to $49 million, only days after revealing a low-cost acquisition of Telstra Health’s Kyra patient flow assets.

Together, the moves are reshaping the narrative around the ASX-listed healthcare technology provider, which has spent recent years steadily building its footprint inside public hospital systems across Australia and the UK.

Shares in Alcidion rose 2.27% to 11.3 cents in late morning trade, giving the company a market value of about $151 million.

Source: MarketIndex 

The larger of the two announcements came through the UK’s National Health Service.

Alcidion secured a seven-year agreement with University Hospitals Sussex NHS Foundation Trust, one of Britain’s largest acute healthcare trusts, servicing roughly one million people across seven hospitals with a workforce of 20,000 staff.

The initial contract is valued at $35 million, with extension options potentially lifting the total value to $49 million over 10 years.

Implementation begins immediately and will run over an 18-month period, with the first operational phase scheduled to go live by June 2027.

Importantly for near-term earnings visibility, Alcidion said approximately $8.5 million in revenue will be recognised during FY26, largely tied to upfront software licensing fees.

The contract centres around deployment of the company’s Miya Precision electronic patient record platform, but the market appears particularly focused on another detail buried inside the release.

The agreement includes the first UK deployment of Alcidion’s Virtual Care module, a remote patient monitoring platform designed to support hospital-at-home models and ease pressure on overloaded healthcare systems.

That matters because Britain’s NHS continues to grapple with severe bed shortages, staffing constraints and mounting demand for digital healthcare infrastructure.

A successful rollout at a trust the size of UHSussex could provide a major reference site for future NHS expansion opportunities.

The acquisition that quietly changed the earnings profile

The NHS deal arrived less than a week after Alcidion announced it would acquire Telstra Health’s Kyra Patient Flow business for an upfront $3 million cash payment, plus a potential $1 million earn-out.

The acquisition price drew immediate attention across the small-cap healthcare sector.

Based on forecast FY26 earnings, the transaction was struck at an upfront EBITDA multiple of roughly 2.7 times, well below valuation levels typically seen across healthcare software deals.

The acquired business is expected to contribute around $3.7 million in FY26 revenue, with more than 90% classified as recurring software income, alongside approximately $1.1 million in underlying EBITDA.

Alcidion is funding the purchase entirely from existing cash reserves. The company held $15.1 million in cash as of March 31 and remains debt free.

The deal also delivers a deeper institutional footprint across Australian hospitals.

Kyra’s products are already embedded across major health networks in Queensland, Victoria, Western Australia and Tasmania, bringing 33 enterprise customers into Alcidion’s orbit. Only two were existing Alcidion customers previously.

That leaves 31 new institutional relationships available for cross-selling Miya Precision and other software products.

The broader healthcare technology sector has increasingly shifted toward recurring revenue and integrated digital infrastructure following years of hospital workforce pressure, rising patient demand and government digitisation spending.

Healthcare systems globally are moving away from fragmented legacy software toward unified platforms capable of handling patient records, workflow coordination, virtual monitoring and operational analytics in one ecosystem.

Alcidion’s recent moves appear designed to accelerate its positioning inside that transition.

Many smaller healthcare software firms have struggled to scale meaningfully because government contracts often favour larger vendors with proven deployments and broader operational footprints.

In the span of a week, Alcidion added both a major NHS validation contract and a profitable customer acquisition with entrenched Australian hospital relationships.

The next major catalyst for the company is likely to be its FY26 reporting cycle, where the market will look closely at recurring revenue growth, integration progress from the Kyra acquisition and the pace of the UK rollout.

For now, the dual announcements suggest Alcidion is shifting from a niche hospital software provider toward a broader infrastructure player inside public healthcare systems.